Abstract | INTRODUCTION:
Letermovir is a new antiviral approved to prevent cytomegalovirus infection in hematopoietic stem cell transplant recipients. It has a distinct mechanism of action as it acts as a terminase complex inhibitor, and shows some advantages compared to the current treatment options for cytomegalovirus infection. Areas covered: This review focuses on the efficacy, safety, pharmacokinetics, pharmacodynamics, and drug-drug interactions of letermovir. Expert opinion: Letermovir is a new antiviral to prevent cytomegalovirus infection. Unlike the currently used polymerase inhibitors, it has a distinct mechanism of action with better safety, limited resistance, and no cross-resistance. Although a lot of research on pharmacokinetics and drug-drug interactions has already been performed, it might be useful to clarify the effect of letermovir on voriconazole exposure, the drug-drug interaction between caspofungine and letermovir and the effect of statins on letermovir exposure. Also, the lack of an exposure-response relationship should be confirmed in large real-life post-marketing studies in order to be able to lower the intravenous dose of letermovir.
|
Authors | Barbara Deleenheer, Isabel Spriet, Johan Maertens |
Journal | Expert opinion on drug metabolism & toxicology
(Expert Opin Drug Metab Toxicol)
Vol. 14
Issue 12
Pg. 1197-1207
(Dec 2018)
ISSN: 1744-7607 [Electronic] England |
PMID | 30479172
(Publication Type: Journal Article, Review)
|
Chemical References |
- Acetates
- Antiviral Agents
- Quinazolines
- letermovir
|
Topics |
- Acetates
(administration & dosage, pharmacokinetics, pharmacology)
- Antiviral Agents
(administration & dosage, pharmacokinetics, pharmacology)
- Cytomegalovirus
- Cytomegalovirus Infections
(etiology, prevention & control)
- Drug Interactions
- Drug Resistance, Viral
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Quinazolines
(administration & dosage, pharmacokinetics, pharmacology)
|